A vial of the Pfizer vaccine versus the coronavirus illness (COVID-19) is seen as medical staff are immunized at Sheba Medical Center in Ramat Gan, Israel December 19, 2020. REUTERS/Amir Cohen/File PhotoSEOUL/JERUSALEM, July 6 (Reuters) – South Korea stated it will receive 700,000 doses of Pfizer-BioNTechs (PFE.N) coronavirus vaccine from Israel on loan this week, in an effort to speed up immunisation following a rise in infections around the capital Seoul.More than 1,000 COVID-19 cases were reported as of 6 p.m. on Tuesday, the greatest given that December and hundreds more than the 746 cases posted on Monday, Yonhap news agency reported, pointing out South Korean government health officials.Under the vaccine swap arrangement revealed by both federal governments on Tuesday, South Korea will provide Israel back the exact same number of shots, already on order from Pfizer, in September and October.South Korea has actually rapidly dispersed the COVID-19 vaccines it has, but has actually had a hard time to obtain adequate doses in a prompt way as global supplies are tight, especially in Asia.Briefing press reporters in Jerusalem, Israeli Prime Minister Naftali Bennett said the vaccines were being packed aboard an airplane within hours of the deals announcement on Tuesday, and that South Korean officials would validate their viability.”After an outstanding roll-out, Israel has administered both shots to around 55% of its population and turnout has plateaued.Korea Disease Control and Prevention Agency (KDCA) Director Jeong Eun-kyeong said the deal would allow South Korea to accelerate its vaccination plans, consisting of supplying shots to staff members in some sectors that have a high quantity of contact with other people.Local authorities will decide who gets the vaccines, but she said priority might be provided to people such as street cleaners, delivery workers and retail employees.South Korean authorities stated last week they were hoping to achieve herd resistance earlier than the present November target by inoculating at least 70% of the population with a minimum of one vaccine dose, primarily mRNA vaccines such as Pfizers.